IP Library › Granted Patent US 9,127,082
Granted Patent B2
US 9,127,082 · App. 12/037,535 · Granted Sep 8, 2015

MANF2 for treatment of Parkinson's disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,127,082
App. No.
12/037,535
Granted
Sep 8, 2015
Kind
B2
Abstract

The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.

Claims (3)

1. A method for treating Parkinson's disease in a patient, comprising:

directly administering to the brain of the patient a pharmaceutically effective amount of a pharmaceutical composition comprising an adenoviral, an adeno-associated viral or a lentiviral vector comprising an expression control sequence operably linked to the MANF2 nucleic acid sequence encoding the MANF2 polypeptide of SEQ ID NO:2 or the mature MANF2 polypeptide consisting of amino acids 27-187 of SEQ ID NO:2.

2. The method according to claim 1 , wherein the vector comprises the MANF2 nucleic acid sequence of SEQ ID NO: 1.